Abstract:The dry root of Scutellaria baicalensis, has traditionally been applied in the treatment of cerebral ischemia in Chinese clinics. Baicalin (BA) is considered the key ingredient in it for the brain protection effects. The bioavailability of BA is very low because of its poor lipid and water solubility, which limits the therapeutic effects and clinical application. The aim of the present study was to develop a novel BA-loaded liposome (BA-LP) formulation to improve the drug lipophilicity and further to enhance the drug-concentration in the brain tissues. This study is also designed to investigate the pharmacokinetics of BA in the pathological conditions of stroke and evaluate the pharmacokinetic differences of BA caused by stroke after intravenous administration with BA and BA-LP. In this study, the novel BA-LP prepared in early stage were characterized by morphology, size, zeta potential, encapsulation rate and the in vitro release. The pharmacokinetics and biodistribution of BA and BA-LP were investigated by intravenous administration in rats with middle cerebral artery occlusion (MCAO) model and normal group respectively. BA-LP had a mean particle size of 160–190 nm, zeta potential of −5.7 mV, and encapsulation efficiency of 42 ± 1%. The BA-LP showed a sustained-release behavior, the in vitro drug-release kinetic model of BA-LP fit well with the biphasic dynamic model equation: Q = 1 − (60.12e0.56t − 59.08e0.0014t). Pharmacokinetic behavior in MCAO rats is not consistent with that of normal rats. The middle cerebral artery occlusion rats got higher Cmax and AUC0–t, which were about 1.5–2 times to normal rats both in BA and liposome groups. In addition, it got especially higher distribution in brain, while BA were not detected in brain tissues on normal rats. The Cmax and AUC0–t values were significantly greater with liposome than BA on both normal and MCAO rats. The tissue distribution behavior was significantly altered in the case of liposome administrated in comparison with BA, which the concentrations in the heart, liver, spleen, lungs and brain were all increased after administrated liposome, but decreased in kidneys. The TI values showed that the target of liposome was improved especially to heart, spleen and brain, and the brain’s target was higher in striatum and cerebellum. In conclusion, BA-LP might be a potential drug delivery system to improve the therapeutic efficacy of BA. In addition, these results also suggest that the pathological damages of ischemia-reperfusion have a significant impact on the pharmacokinetic traits of BA.

Pharmacokinetic Study of Brucine Liposomes in Rats

Pharmacokinetics of brucine in rats after intravenous administration of liposomes containing total alkaloids from seed of Strychnos nux-vomica

Effect of Phospholipids on Pharmacokinetics of Liposomes Loaded with Brucine in Rats

Pharmacokinetics of brucine after intravenous and oral administration to rats.

Evaluation of the Pharmacodynamics and Pharmacokinetics of Brucine Following Transdermal Administration.

[In Vitro Transdermal Permeation and Penetration Properties for Transfersomes of Brucine].

HPLC Determination of Brucine in Rat Plasma

Comparison of Antitumor Effect Between Brucine and Its Liposome in Mice Transplanted with Tumor in Vivo

Preparation and pharmacokinetics of brucine immuno-nanoparticles

Effect of Phospholipid Composition on Pharmaceutical Properties and Anti-Tumor Activity of Stealth Liposomes Containing Brucine

Plasma Pharmacokinetics and Tissue Distribution Study of Physalin D in Rats by Ultra-Pressure Liquid Chromatography with Tandem Mass Spectrometry

Anticancer effect and toxicity of brucine and brucine liposome in mice with transplant Heps tumors in vivo

Determination of Brucine in the Tissues of Tumor-bearing Mice by HPLC Method

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Comparative study on pharmacokinetics of extract from Bufonis venenum and its liposomes

Determination of 4-Chloro-2-fluoro-3-methoxybenzeneboronic Acid in Rat Plasma by LC-MS/MS and Its Application in the Toxicokinetics Study

Preparation, Characterization, Pharmacokinetics and Biodistribution of Baicalin-Loaded Liposome on Cerebral Ischemia-Reperfusion after i.v. Administration in Rats

Effect of Phospholipid Composition on Pharmacokinetics of Liposomes Containing Total Alkaloids from Seed of Strychnos nux-vomica L.

Comparison of Pharmacokinetics of Baicalein and Baicalin in Rats

Pharmacokinetic Studies of Baicalin and Compatibility of Baicalin-Panax Notoginsenosides in Rat Cerebrospinal Fluid

Characterization, biodistribution and targeting evaluation of breviscapine lipid emulsions following intravenous injection in mice.